mudpecker, siRNA and other nucleotide-based therapies are drugs if they are used to treat patients. They have to show a reasonable benefit to human patients (not mice - there is a huge difference) before they are approved. In addition the benefits must far outweigh any potential side effects. This hasn't and won't change. Otherwise these companies would not go through the time and money-consuming clinical trial phases. The technology certainly has some promising appeal, but dont forget that BLT is not alone - there are dozens of startups and big pharma companies competing world-wide, but most likely only a few will make it. Sure, there is some potential in this company, but I cant see any short-term event that either drives the SP north or de-risks this company. just my opinion CHeers and good luck
BLT Price at posting:
37.5¢ Sentiment: None Disclosure: Not Held
